Main Industry
Biotechnology
Main Product/Service
EliteCell’s product portfolio includes the “EliteGro™” human‑platelet‑lysate (hPL) line—animal‑serum‑free and xenogeneic‑free cell‑culture supplements for research and commercial cell‑expansion applications; the “EL837” serum‑free lymphocyte culture mediu
The content above was translated by Ai
Founded Year
2017
Unified Business No.
55627837
Status
Active
Number of Employees
0
Total Paid-in
Capital
3,354,480 (NT$)
Location of Company
Taiwan
, New Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Biomedical EliteCell Corp. focuses on providing safe and effective cell‑culture products for the cell‑therapy industry and research community. With over a decade of cGMP manufacturing experience in the cell supplement market, the company collaborates with USA FDA‑licensed and AABB‑accredited blood centers to ensure 100 % raw‑material traceability. Its Texas‑based cGMP‑compliant facility features an integrated quality‑management system and operates under FDA 21 CFR Part 820 regulations.
The content above was translated by Ai
